For millions of people living with metabolic dysfunction-associated steatohepatitis (MASH), treatment options remain limited. The progressive form of fatty liver disease develops when excess fat accumulates in the liver, leading to inflammation, tissue damage and fibrosis—the buildup of scar tissue that can eventually cause cirrhosis, liver failure and the need for a transplant. Although the first medications for MASH have recently become available, they are intended only for patients with advanced disease and have common side effects.